Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 1Gastrointestinal 1

Conditions

Solid Tumors 1Pancreatic Neoplasms 1Haematological Malignancies 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × MSC1992371A × Clear all
NCT00391521 2014-01-30

AS703569 Phase I in Patients With Solid Tumours

EMD Serono

Phase 1 Completed
104 enrolled
Other solid neoplasm

Solid Tumors

NCT01097512 2014-01-30

AS703569 and Gemcitabine Combination in Advanced Malignancies

Merck KGaA, Darmstadt, Germany

Phase 1 Completed
66 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT01080664 2013-10-22

A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies

EMD Serono

Phase 1 Terminated
124 enrolled

Haematological Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡